| Peripheral T-Cell Lymphoma
Beleodaq vs Folotyn
Side-by-side clinical, coverage, and cost comparison for peripheral t-cell lymphoma.Deep comparison between: Beleodaq vs Folotyn with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsFolotyn has a higher rate of injection site reactions vs Beleodaq based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Folotyn but not Beleodaq, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Beleodaq
Folotyn
At A Glance
IV infusion
Once daily, days 1-5 of 21-day cycle
HDAC inhibitor
IV infusion
Once weekly
Dihydrofolate reductase inhibitor
Indications
- Peripheral T-Cell Lymphoma
- Peripheral T-Cell Lymphoma
Dosing
Peripheral T-Cell Lymphoma 1,000 mg/m2 administered over 30 minutes by IV infusion once daily on days 1 through 5 of a 21-day cycle; cycles repeated until disease progression or unacceptable toxicity.
Peripheral T-Cell Lymphoma 30 mg/m2 IV over 3-5 minutes once weekly for 6 weeks in 7-week cycles; reduce to 15 mg/m2 for severe renal impairment (eGFR 15-29 mL/min/1.73 m2); avoid in ESRD (eGFR <15 mL/min/1.73 m2) unless benefit justifies risk; pretreat with folic acid 1-1.25 mg orally daily (starting 10 days before first dose) and vitamin B12 1 mg IM every 8-10 weeks (starting within 10 weeks before first dose).
Contraindications
—
—
Adverse Reactions
Most common (>=10%) nausea, fatigue, pyrexia, anemia, vomiting, constipation, diarrhea, dyspnea, rash, peripheral edema, cough, thrombocytopenia, pruritus, chills, increased blood lactate dehydrogenase, decreased appetite, headache, infusion site pain, hypokalemia, prolonged QT, abdominal pain, hypotension, phlebitis, dizziness
Serious pneumonia, pyrexia, infection, anemia, increased creatinine, thrombocytopenia, multi-organ failure
Most common (>=35%) Mucositis, thrombocytopenia, nausea, fatigue
Serious Pyrexia, mucositis, sepsis, febrile neutropenia, dehydration, dyspnea, thrombocytopenia
Postmarketing Toxic epidermal necrolysis
Pharmacology
Beleodaq is a histone deacetylase (HDAC) inhibitor that causes accumulation of acetylated histones and other proteins in vitro, inducing cell cycle arrest and/or apoptosis of transformed cells with preferential cytotoxicity towards tumor cells compared to normal cells.
Pralatrexate is a folate analog metabolic inhibitor that competitively inhibits dihydrofolate reductase and polyglutamylation by folylpolyglutamyl synthetase, depleting thymidine and other biological molecules dependent on single carbon transfer.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Beleodaq
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (0/12)
Folotyn
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Beleodaq
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Folotyn
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Beleodaq
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Folotyn
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableCancerCare: Non-Hodgkin Lymphoma
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableCancerCare: Non-Hodgkin Lymphoma
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
BeleodaqView full Beleodaq profile
FolotynView full Folotyn profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.